Analysts: more sales Evotec

Next Monday the German Evotec will report its past quarter's results. For this year Evotec 's revenue will be around 246,86 million euros. This is according to the average of the analysts' estimates. This is rather significant more than 2016's revenue of 164,51 million euros.

Historical revenues and results Evotec plus estimates 2018

The analysts expect for 2018 a net profit of 29 million euros. According to most of the analysts the company will have a profit per share for this book year of 25 cent. Based on this the price/earnings-ratio is a huge 61,48.

For this year analysts don't expect the company to pay a dividend.The average dividend yield of the pharmaceutical companies equals a moderate 1 percent.

Latest estimates around 18 euros

Berenberg, Oddo Seydler Bank and Deutsche Bank recently provided recommendations for the stock.

Evotec 's market capitalization is around 2,03 billion euros.

At 10.14 the stock trades 1,76 percent lower at 15,37 euros.

Historical stock prices Evotec

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.